Challenges of managing chronic pain in the elderly

Seminars in Arthritis and Rheumatism

Volumn 32, Issue 3 SUPPL. 1, 2002, Pages 43-50

  Ruoff, Gary E ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Westside Family Medical Center   (United States)

Author keywords

Chronic pain; Contraindications; COX 2 inhibitors; Elderly; NSAID

Indexed keywords

CELECOXIB; IBUPROFEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; VALDECOXIB;

CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; DIGESTIVE SYSTEM ULCER; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFLAMMATION; LOW BACK PAIN; NEPHROTOXICITY; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

EID: 0036936417     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2002.37214     Document Type: Review

References (58)

1. Lamberg L. New guidelines on managing chronic pain in older persons. JAMA 1998;280:311.
2. Slyk M. Practice guidelines for treatment of chronic pain in the elderly. Am Soc Consultant Pharmacists 1999;14(suppl 6).
3. Belostocki KB, Paget SA. Inflammatory rheumatologic disorders in the elderly. Unusual presentations, altered outlooks. Postgrad Med 2002;111:72-4, 7-8, 81-3.
4. Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999:14:231-9.
5. Ruoff G. Management of pain in patients with multiple health problems: A guide for the practicing physician. Am J Med 1998;105:53S-60S.
6. Landi F, Onder G, Cesari M, Gambassi G, Steel K, Russo A, et al. Pain management in frail, community-living elderly patients. Arch Intern Med 2001;161:2721-4.
7. The management of chronic pain in older persons (clinical practice guidelines) - AGS panel on chronic pain in older persons. J Am Geriatr Soc 1998;46:635-51.
8. Cooner E, Amorosi S. The Study of Pain and Older Americans. Study Conducted for the National Council on the Aging. New York: Louis Harn's and Associates, 1997, Study No. 628200.
9. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet 1999;354:1248-52.
10. Herr K. Chronic pain in the older patient: Management strategies [quiz 54-5]. 2. J Gerontol Nuts 2002;28:28-34.
11. Gloth FM. 3rd. Concerns with chronic analgesic therapy in elderly patients. Am J Med 1996;101:19S-24S.
12. Miaskowski C. The impact of age on a patient's perception of pain and ways it can be managed. Pain Manag Nurs 2000;1:2-7.
13. Prevalence of disabilities and associated health conditions-United States. 1991-1992. MMWR 1994;43:730-1, 7-9.
14. Prevalence of disabilities and associated health conditions among adults - United States 1999. MMWR 2001;50:120-5.
15. Schnitzer T, Hochberg MC. COX-2 selective inhibitors in the treatment of arthritis. Cleve Clin J Med 2002;69:SI-20-SI-30.
16. Lister BJ. Dilemmas in the treatment of chronic pain. Am J Med 1996;101:2S-5S.
17. Davies N, Wallace J. Selective inhibitors of cyclooxygenase-2. Potential in elderly patients. Drugs Aging 1996;9:406-17.
18. Katz WA. Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases. Curr Opin Rheumatol 2002;14:63-71.
19. Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 2002;46:328-46.
20. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient. Gastroenterology 2001;120:594-606.
21. Laine L, Bombardier C, Ramey DR, Watson DJ, Pellissier JM, Reicin A. Less use of gastrointestinal (GI) protective agents and GI-related procedures with Rofecoxib vs. Naproxen in the VIGOR (Vioxx GI Outcomes Research) study. Paper presented at: EULAR 2001; June 13-16, 2001; Prague, Czech Republic.
22. Wolfe F, Kong SX, Watson DJ. Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol 2000;27:1373-8.
23. Wolfe MM. NSAIDs and the gastrointestinal mucosa. Hospital Practice 1996;37-47.
24. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2 p following 8.
25. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
26. Silverstein F, Simon L, on behalf of the CLASS Investigators. Celecoxib is associated with a lower incidence of serious GI toxicity relative to nonsteroidal anti-inflammatory drugs (NSAIDs) - The Celecoxib Long-term Arthritis Safety Study (CLASS) [abstract 1907]. Arthritis Rheum 2000;43(9 Suppl):S384.
27. Singh G, Terry R, Ramey DR, Halpern J, Brown W. Comparative GI toxicity of NSAIDs. Paper presented at: XIX ILAR Congress of Rheumatology; June 8-13, 1997; Abstract.
28. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
29. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-32.
30. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25:373-93.
31. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
32. Chodosh J, Ferrell BA, Shekelle PG, Wenger NS. Quality indicators for pain management in vulnerable elders. Ann Intern Med 2001;135:731-5.
33. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988:109:359-63.
34. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
35. Bombardier C, Laine L, Reicin AS, Shapiro DR, Sperling RS. Risk factors for clinically important upper GI events: The VIGOR study. Paper presented at: EULAR 2001; June 13-16, 2001; Prague, Czech Republic.
36. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26(suppl 56):18-24.
37. Singh G, Rosen Ramey DR. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. Arthritis. Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998;51:8-16.
38. MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000;284:984-92.
39. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
40. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107:65S-71S.
41. Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension; alternative analgesics for patients at risk. Clin Ther 1998;20:376-87.
42. Yost JH, Morgan CJJ. Cardiovascular effects of NSAIDs. J Musculoskel Med 1994;11:22-34.
43. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DC. Effects of acute and chronic dosing of nonsteroidal anti-inflammatory drugs in patients with renal insufficiency. Kidney Int 1986;30:760-8.
44. Henry D. Meta-analysis of risk of gastrointestinal complications with NSAIDs: Authors should not have included data from one study. BMJ 1997;314:445.
45. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal functions: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
46. Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 1987:147:85-8.
47. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
48. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4-13.
49. Celebrex (Celecoxib). U.S. Prescribing Information. Kalamazoo, MI: Pharmacia, 2000.
50. Vioxx (Rofecoxib). U.S. Product Information. West Point, PA: Merck & Co, 2000.
51. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-7.
52. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
53. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999;282:1921-8.
54. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: A randomized trial. JAMA 2002;287:64-71.
55. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-8.
56. Helme RD. Chronic pain management in older people. Eur J Pain 2001;5 Suppl A:31-6.
57. Whelton A, Brater DC, Sica DA. Effects of celcoxib and naproxen on renal function in the elderly [abstract]. J Am Soc Nephrol 1999;10:92A.
58. Catella-Lawson F, McAdam B, Morrison B, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41.